Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to updated findings from the phase 2 DREAMM-2 trial presented as part of the 2020 ASCO Virtual Scientific Program.
In a 13-month follow-up analysis, the overall response rate (ORR) was 32% (31/97; 97.5% CI, 21.7%-43.6%) for patients treated in the 2.5-mg/kg cohort and 35% (35/99; 97.5% CI, 23.9%-46.0%) in the 3.4-mg/kg cohort.
The duration of response (DoR) was not reached (NR) in either cohort. The median DoR estimate was 11.0 months (95% CI, 4.2-NR) and 6.2 months (95% CI, 4.8-NR), respectively. Further, more than half of patients who achieved a response in both cohorts, had a very good partial response (VGPR) or better (58% and 66%, respectively).1
The VGPR analyses included 11 patients with VGPR,…